CLAIMS

1. New hormonal pharmaceutical compositions characterized in that they are formed by a combined estroprogestative combination which allows the simultaneous administration of an estrogenic component and a progestative component, in combination or as a mixture with one or more pharmaceutically acceptable, inert, non-toxic excipients, intended for administration by oral route.

2. Estroprogestative compositions according to claim 1, in which the estrogen is free or esterified estradiol or equine conjugated estrogens.

3. Estroprogestative compositions according to claim 1 or claim 2, in which the estrogen is an ester of estradiol and in particular estradiol valerate.

4. Estroprogestative compositions according to one of claims 1 to 3, in which the free or esterified estradiol or an equine conjugated estrogen is present at a dose ranging from 0.5 to 3 mg per unit dose.

5. Estroprogestative compositions according to claim 4, in which the free estradiol is preferably present at a dose of 1.5 mg per unit dose.

6. Estroprogestative compositions according to claim 4, in which the ester of estradiol is preferably present at a dose of 2 mg per unit dose.

7. Estroprogestative compositions according to claim 4, in which the equine conjugated estrogen is preferably present at a dose of 0.625 mg per unit dose.

8. Estroprogestative compositions according to claim 1, in which the progestative is nomegestrol acetate.

9. Estroprogestative compositions according to claims 1 and 8, in which the nomegestrol acetate is present at a dose ranging from 1.5 to 3.75 mg per unit dose.

10. Estroprogestative compositions according to claim 9, in which the nomegestrol acetate is preferably present at a dose of 2.5 mg per unit dose.

11. Use of an estroprogestative mixture according to one of claims 1 to 10, with a view to the production of a medicament intended for the treatment of estrogenic deficiencies in post-menopausal women.

12. Use of an estroprogestative mixture according to one of claims 1 to 10, with a view to the production of a medicament intended for the prevention of osteoporosis and cardiovascular illnesses in post-menopausal women.

13. Use of an estroprogestative mixture according to one of claims 1 to 10, with a view to the production of a medicament intended to be administered to women during their period of ovarian activity in order to stop ovulation.

14. Use of an estroprogestative mixture according to one of claims 1 to 10 with a view to the production of a medicament intended to be administered in a continuous or intermittent fashion.

15. A preparation process for new estroprogestative compositions according to one of claims 1 to 10, which consists of mixing the estrogenic active ingredient and the progestative active ingredient with one or more pharmaceutically acceptable, non-toxic, inert excipients.